Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 7758-94-3
2. Dichloroiron
3. Fecl2
4. Iron(2+) Chloride
5. Iron (ii) Chloride
6. Iron(ii)chloridetetrahydrate
7. Iron(ii) Chloride, Anhydrous
8. Mfcd00011004
9. Ferrous Dichloride
10. Iron Protochloride
11. Natural Lawrencite
12. Ferro 66
13. Iron Chloride (fecl2)
14. Iron(ii) Chloride (1:2)
15. Hsdb 459
16. Fe(ii) Chloride
17. Einecs 231-843-4
18. Na1759
19. Iron (11) Chloride
20. Ferrous Chloride, Solid
21. [fecl2]
22. Ferrous Chloride, Solution
23. Unii-s3y25php1w
24. Iron(ii) Chloride, 98%
25. Iron(ii) Chloride, Ultra Dry
26. Chebi:30812
27. Akos015902899
28. Sc10849
29. Ncgc00248559-01
30. Ft-0689813
31. Ec 231-843-4
32. Ferrous Chloride, Solid [na1759] [corrosive]
33. Q407867
34. Ferrous Chloride, Solution [na1760] [corrosive]
35. Iron(ii) Chloride, Anhydrous, Beads, -10 Mesh, 99.9% Trace Metals Basis
36. Iron(ii) Chloride, Anhydrous, Beads, -10 Mesh, 99.99% Trace Metals Basis
37. Iron(ii) Chloride, Anhydrous, Beads, -10 Mesh, 99.998% Trace Metals Basis
| Molecular Weight | 126.75 g/mol |
|---|---|
| Molecular Formula | Cl2Fe |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 0 |
| Rotatable Bond Count | 0 |
| Exact Mass | 125.872641 g/mol |
| Monoisotopic Mass | 125.872641 g/mol |
| Topological Polar Surface Area | 0 Ų |
| Heavy Atom Count | 3 |
| Formal Charge | 0 |
| Complexity | 2.8 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Ferrous /salts/ are ... available ... for ... prevention and treatment of iron deficiency. /Iron preparations, oral/
McEvoy, G.K. (ed.). AHFS Drug Information 90. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1990 (Plus Supplements 1990)., p. 716
IRON CMPD ARE CONTRAINDICATED IN PATIENT WITH PRIMARY HEMOCHROMATOSIS. THEY SHOULD NOT BE USED TO TREAT HEMOLYTIC ANEMIAS UNLESS IRON-DEFICIENT STATE ALSO EXISTS, SINCE STORAGE OF IRON WITH POSSIBLE SECONDARY HEMOCHROMATOSIS CAN RESULT. IRON OVERLOAD IS PARTICULARLY LIKELY TO OCCUR IN PATIENT GIVEN EXCESSIVE AMT OF PARENTERAL IRON, IN THOSE TAKING BOTH ORAL & PARENTERAL PREPN, & IN PATIENT WITH HEMOGLOBINOPATHIES OR OTHER REFRACTORY ANEMIAS THAT MIGHT BE ERRONEOUSLY DIAGNOSED AS IRON DEFICIENCY ANEMIAS. IRON SHOULD NOT BE GIVEN TO PATIENT RECEIVING REPEATED BLOOD TRANSFUSIONS ... . PROLONGED ADMIN SHOULD BE AVOIDED EXCEPT IN PATIENT WITH CONTINUED BLEEDING, INCL UNCORRECTABLE MENORRHAGIA, COPIOUS MENSTRUAL PERIODS, OR REPEATED PREGNANCIES. /IRON CMPD/
American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 98
... Studies on ... subjects have established that physical intolerance does occur. With a dose of 200 mg of iron per day divided into three equal portions, symptoms occurred in approximately 25% of individuals, compared to an incidence of 13% among those receiving placebos; this increased to 42% when the dosage of iron was doubled. Nausea and upper abdominal pain were increasingly common manifestations at high dosage. Constipation and diarrhea ... were not more prevalent at higher dosage, nor was heartburn. /Iron & iron salts/
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1324
... LARGE AMT MAY INTERFERE WITH SOME TESTS USED FOR DETECTION OF OCCULT BLOOD IN STOOL; GUAIAC TEST OCCASIONALLY YIELDS FALSE-POSITIVE TESTS FOR BLOOD ... . /IRON SALTS/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1317
Malabsorption syndromes (eg, tropical sprue, celiac disease, partial gastrectomy) and apparent intolerance to iron usually do not constitute valid indications for parenteral iron therapy. Marked malabsorption of iron is rare. Following gastric resection, rapid transit past the duodenum may reduce absorption. However, even in these patients, absorption usually is adequate to produce a therapeutic response, particularly if a liquid preparation is used. Intolerance probably is dose related and may be corrected by decreasing the size of each dose. /Iron/
American Medical Association, Department of Drugs. Drug Evaluations. 6th ed. Chicago, Ill: American Medical Association, 1986., p. 590
As little as 1 to 2 g of iron may cause death ... /in child/. /Ferrous salts/
Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 1291
ORAL ABSORPTION OF IRON IS VERY COMPLICATED & INTESTINAL MUCOSA IS PRINCIPAL SITE FOR LIMITING ABSORPTION ... IN THIS HOMEOSTATIC MECHANISM DIVALENT FORM IS ABSORBED INTO GI MUCOSA & CONVERTED TO TRIVALENT FORM & ATTACHED TO FERRITIN. ... /WHICH/ PASSES INTO BLOODSTREAM & IS THEN CONVERTED TO TRANSFERRIN WHERE THE IRON REMAINS IN THE TRIVALENT FORM OR IS TRANSPORTED TO THE LIVER OR SPLEEN FOR STORAGE AS FERRITIN OR HEMOSIDERIN. IRON HAS BEEN SHOWN TO CROSS PLACENTA & CONCENTRATE IN FETUS. ... WITH INCREASES IN IRON BEYOND PHYSIOLOGIC LIMITS, MOST IS EXCRETED IN FECES, BUT SMALL AMT MAY ACCUM. SOME IRON MAY BE EXCRETED VIA THE BILE. IN CASES OF OVERLOAD, IRON IS EXCRETED IN THE URINE, & THE PRESENCE OF HIGH URINARY IRON CONCN IS INDICATIVE OF EXCESSIVE IRON. /IRON SALTS/
Doull, J., C.D. Klaassen, and M. D. Amdur (eds.). Casarett and Doull's Toxicology. 2nd ed. New York: Macmillan Publishing Co., 1980., p. 446
The body store of iron is divided between iron-containing cmpd that are essential and those in which excess iron is held in storage. ... Hemoglobin dominates the essential fraction. ... The two predominant sites of iron storage are the reticuloendothelial system and the hepatocytes, although some storage also occurs in muscle ... . Internal exchange of iron is accomplished by the plasma protein transferrin. ... About 80% of the iron in plasma goes to the erythroid marrow to be packaged into new erythrocytes; these normally circulate for about 120 days before being catabolized by the reticuloendothelium. At that time a portion of the iron is immediately returned to the plasma bound to transferrin, while another portion is incorporated into the ferritin stores of the reticuloendothelial cell and is returned to the circulation more gradually. /Iron & iron salts/
Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 1283
The most remarkable feature of iron metabolism in man is the degree to which the body store is conserved. Only 10% of the total is lost per year from normal men, that is, about 1 mg per day ... . Two thirds of this iron is excreted from the GI tract as extravasated red cells, iron in bile, and iron in exfoliated mucosal cells. The other third is accounted for by small amounts of iron in desquamated skin and in the urine. ... The biochemical nature of the absorptive process is understood only in general terms ... . After acidification and partial digestion of food in the stomach, its content of iron is presented to the intestinal mucosa as either inorganic or heme iron. These fractions are taken up by the absorptive cells of the duodenum and upper small intestine, and the iron is either transported directly into the plasma or is stored as mucosal ferritin. ... Normal absorption is about 1 mg per day in the adult male and 1.4 mg per day in the adult female. /Iron & iron salts/
Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 1284
Substantial amounts of many metals are excreted in the sweat, including ... iron. ... The potential exists, depending on sweat rates and acclimatization, for substantial losses of these metals in sweat. /Iron salts/
Doull, J., C.D.Klassen, and M.D. Amdur (eds.). Casarett and Doull's Toxicology. 3rd ed., New York: Macmillan Co., Inc., 1986., p. 418
IN CELL FE++ ... CONVERTED TO FE+++ IN FERRITIN. NO IRON ABSORPTION AS FERRITIN OCCURS UNTIL CELL IS PHYSIOLOGICALLY "DEPLETED." FE, HOWEVER, IS WITHDRAWN FROM FERRITIN AS FE++ AS NEED ARISES. FE RELEASED DIRECTLY INTO BLOOD STREAM ... QUICKLY OXIDIZED BY DISSOLVED O2 TO FE+++ WHICH COMPLEXES WITH SPECIFIC FE-TRANSPORT B1-GLOBULIN ... . /IRON IONS/
Clayton, G. D. and F. E. Clayton (eds.). Patty's Industrial Hygiene and Toxicology: Volume 2A, 2B, 2C: Toxicology. 3rd ed. New York: John Wiley Sons, 1981-1982., p. 1667
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
ABOUT THIS PAGE
A Ferrous Chloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ferrous Chloride, including repackagers and relabelers. The FDA regulates Ferrous Chloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ferrous Chloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ferrous Chloride supplier is an individual or a company that provides Ferrous Chloride active pharmaceutical ingredient (API) or Ferrous Chloride finished formulations upon request. The Ferrous Chloride suppliers may include Ferrous Chloride API manufacturers, exporters, distributors and traders.
click here to find a list of Ferrous Chloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ferrous Chloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Ferrous Chloride active pharmaceutical ingredient (API) in detail. Different forms of Ferrous Chloride DMFs exist exist since differing nations have different regulations, such as Ferrous Chloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ferrous Chloride DMF submitted to regulatory agencies in the US is known as a USDMF. Ferrous Chloride USDMF includes data on Ferrous Chloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ferrous Chloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ferrous Chloride suppliers with USDMF on PharmaCompass.
Ferrous Chloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ferrous Chloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ferrous Chloride GMP manufacturer or Ferrous Chloride GMP API supplier for your needs.
A Ferrous Chloride CoA (Certificate of Analysis) is a formal document that attests to Ferrous Chloride's compliance with Ferrous Chloride specifications and serves as a tool for batch-level quality control.
Ferrous Chloride CoA mostly includes findings from lab analyses of a specific batch. For each Ferrous Chloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ferrous Chloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Ferrous Chloride EP), Ferrous Chloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ferrous Chloride USP).
LOOKING FOR A SUPPLIER?
